| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00535-010-0358-6 |
| P698 | PubMed publication ID | 21246384 |
| P50 | author | Namiki Izumi | Q90377862 |
| Hiromitsu Kumada | Q114433568 | ||
| C Nelson Hayes | Q87781870 | ||
| Kazuaki Chayama | Q87781872 | ||
| P2093 | author name string | Akihiro Matsumoto | |
| Yoshiyuki Ueno | |||
| Shotaro Sakisaka | |||
| Hisataka Moriwaki | |||
| Makoto Oketani | |||
| Masataka Seike | |||
| Tetsuo Takehara | |||
| Hideyuki Nomura | |||
| Kentaro Yoshioka | |||
| Joji Toyota | |||
| Yoichi Hiasa | |||
| Hiroshi Yotsuyanagi | |||
| Takashi Okanoue | |||
| P2860 | cites work | Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses | Q27472905 |
| Viral Determinants of Resistance to Treatment in Patients with Hepatitis C | Q27478062 | ||
| Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region | Q27478292 | ||
| Expert opinion on the treatment of patients with chronic hepatitis C | Q27489903 | ||
| Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis | Q27860811 | ||
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 | ||
| Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection | Q29620702 | ||
| Predictive model of biliocystic communication in liver hydatid cysts using classification and regression tree analysis | Q33557668 | ||
| Hepatitis C: the clinical spectrum of the disease | Q33809411 | ||
| Classification of chronic hepatitis: diagnosis, grading and staging | Q40755087 | ||
| Hepatitis C: the clinical spectrum of disease | Q41598735 | ||
| Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response | Q42670765 | ||
| Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy | Q42978970 | ||
| Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin | Q42983450 | ||
| A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. | Q42984537 | ||
| Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy | Q42985561 | ||
| Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy | Q42986366 | ||
| Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial | Q42986993 | ||
| Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study | Q42988539 | ||
| Mutation frequency of NS5A in patients vertically infected with HCV genotype 1 predicts sustained virological response to peginterferon alfa-2b and ribavirin combination therapy | Q42990154 | ||
| Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. | Q42991459 | ||
| Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response | Q42992693 | ||
| Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region | Q42993153 | ||
| Hepatitis C virus genotype 1a NS5A pretreatment sequence variation and viral kinetics in African American and white patients | Q42994490 | ||
| Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. | Q42996720 | ||
| Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection | Q42998237 | ||
| Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin | Q42999474 | ||
| Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. | Q43001787 | ||
| Evaluation of quantitative measurements of hepatitis C virus RNA to predict sustained response to interferon by genotype | Q43031752 | ||
| Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest | Q43033968 | ||
| Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera | Q43037304 | ||
| A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis | Q43195684 | ||
| Predicting early mortality after acute variceal hemorrhage based on classification and regression tree analysis. | Q43287759 | ||
| Prolonged treatment with pegylated interferon alpha 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan. | Q50561652 | ||
| Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. | Q50569718 | ||
| Hepatitis C | Q74751759 | ||
| P433 | issue | 4 | |
| P921 | main subject | virology | Q7215 |
| P304 | page(s) | 545-555 | |
| P577 | publication date | 2011-01-19 | |
| P1433 | published in | Journal of Gastroenterology | Q15764399 |
| P1476 | title | Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C. | |
| P478 | volume | 46 |
| Q33766292 | Assessment of total hepatitis C virus (HCV) core protein in HCV-related mixed cryoglobulinemia |
| Q45362979 | Favorable factors for re-treatment with pegylated interferon α2a plus ribavirin in patients with high viral loads of genotype 1 hepatitis C virus |
| Q44239267 | Fish to meat intake ratio and cooking oils are associated with hepatitis C virus carriers with persistently normal alanine aminotransferase levels |
| Q43039948 | Gene expression patterns in livers of Hispanic patients infected with hepatitis C virus |
| Q26782405 | HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy |
| Q45359763 | Response-guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2. |
| Q41294797 | The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay |
| Q40581238 | Understanding Determinants of Racial and Ethnic Disparities in Viral Load Suppression. |
Search more.